Effect of nafamostat mesilate on coagulation and fibrinolysis in hepatic resection.

Mitsuo Shimada(Tokushima University), K Sugimachi(National Hospital Organization Kyushu Cancer Center), Ken Shirabe(Gunma University), Tsukasa Kamakura(National Cerebral and Cardiovascular Center), Akinobu Taketomi(Hokkaido University), Takashi Matsumata(Kyushu University)

PubMed

May 1, 1994

Cited by 30

Related Papers

Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH‐HCC guidelines) 2019 update

|Hepatology Research|2019|539

Randomized clinical trial of adjuvant gemcitabine chemotherapy <i>versus</i> observation in resected bile duct cancer

|British journal of surgery|2018|401

Interleukin‐6/<scp>STAT</scp>3 signaling as a promising target to improve the efficacy of cancer immunotherapy

|Cancer Science|2017|295

Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2021 version (5th JSH‐HCC Guidelines)

|Hepatology Research|2023|281

Genome-wide Association Study Identifies TNFSF15 and POU2AF1 as Susceptibility Loci for Primary Biliary Cirrhosis in the Japanese Population

|The American Journal of Human Genetics|2012|272